Emmaus Life Sciences licenses Endari to NeoImmuneTech for US/Canada with upfront and royalties

Emmaus Life Sciences, Inc.

Emmaus grants NeoImmuneTech (NIT) exclusive rights to market Endari for sickle cell disease in US and Canada; upfront payment plus royalty on NIT sales.
Effective date conditioned on NIT obtaining regulatory approvals; either party may terminate if not met by Oct 1, 2026.
Emmaus will supply Endari to NIT at cost-plus margin; selected US sales force to transfer to NIT pending effective date.
If NIT fails to meet annual minimum sales, the license becomes non-exclusive.
Emmaus CEO says deal allows refocus on higher-growth regions: Middle East, Brazil, Europe.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Emmaus Life Sciences, Inc. entered into License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. valued at an upfront payment (effective 2025-12-24).

Action: entry
Agreement: license
Counterparty: NeoImmuneTech, Inc.
Value: an upfront payment
Effective: 2025-12-24

Exact text from the filing

On December 24, 2025, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” and the “company”) and NeoImmuneTech, Inc. (KOSDAQ: 950220.KQ), or NIT, entered into a License and Exclusive Distribution Agreement, or License Agreement, dated as of the same day pursuant to which we granted NIT an exclusive (including as to Emmaus) license to all our rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents, or the Products, in sickle cell disease, or the Field, in the U.S. and its territories and possession and Canada, referred to as the Territory, in exchange for an upfront payment and a royalty on NIT’s Product sales.

View on SEC.gov

314 material agreements filed in the last 30 days. Browse all material agreements →

Emmaus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-126728

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.